Oxymorphone hydrochloride

USDailyMed:Oxymorphone N02AA11(WHO) AU:S8(Controlled drug)BR:Class A1(Narcotic drugs)CA:Schedule IDE:Anlage II(Authorized trade only, not prescriptible)UK:Class AUS:Schedule II 4,5α-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one 76-41-5Y 5284604 7094 DB01192Y 4447650Y 9VXA968E0C D08323Y ChEMBL963Y DTXSID5023409 Interactive image CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5 InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1YKey:UQCNKQCJZOAFTQ-ISWURRPUSA-NY Oxymorphone(sold under the brand namesNumorphanandOpanaamong others) is a highly potentopioidanalgesicindicated for treatment of severe pain.‍‍‍‍‍‍​​​‍​​​​​​ Pain relief after injection begins after about 5–10 minutes; after oral administration it begins after about 30 minutes and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets.The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally.Likeoxycodone, which metabolizes to oxymorphone, oxymorphone has a high abuse potential. Oxymorphone was developed in Germany in 1914. It was patented in 1955 and approved for medical use in 1959.In June 2017 theFDAaskedEndo Pharmaceuticalsto remove its product from the US market.This was in part due to theopioid epidemicin the US, and the fact that a 2012 reformulation failed to stop illicit injection of the drug. Endo responded by voluntarily removing Opana ER from the market a month later.Generic versions of extended-release oxymorphone, such as those manufactured byAmneal Pharmaceuticals, are still available in the US.